초록 ▼

● 지재권 확보가능성 분석결과, 원천특허의 확보 가능 지수가 4.7/5.0로 “매우 높음”으로 분석되었음
● 학계, 의료계, 산업계 전문가들로부터 기획연구의 목적 및 연구내용에 대한 컨설팅 의견과 기획연구 기술의 우수성과 차별성에 대해 긍정적 평가를 받았음
● “고변이 바이러스에 능동 대응할 수 있는 크기와 기능이 조절 가능한 단백질-고분자 혼성 Protein NanoBall 원천기술 확립”을 최종 목표로 설정하였음
● 주요 연구내용이 단백질-고분자 혼성 나노구조체 단위블럭 조립, 미세유체제조기술, 면역백신 성능평가

● 지재권 확보가능성 분석결과, 원천특허의 확보 가능 지수가 4.7/5.0로 “매우 높음”으로 분석되었음
● 학계, 의료계, 산업계 전문가들로부터 기획연구의 목적 및 연구내용에 대한 컨설팅 의견과 기획연구 기술의 우수성과 차별성에 대해 긍정적 평가를 받았음
● “고변이 바이러스에 능동 대응할 수 있는 크기와 기능이 조절 가능한 단백질-고분자 혼성 Protein NanoBall 원천기술 확립”을 최종 목표로 설정하였음
● 주요 연구내용이 단백질-고분자 혼성 나노구조체 단위블럭 조립, 미세유체제조기술, 면역백신 성능평가의 3개 세부과제로 도출되었음
● 특이적 상호작용을 도입하여 단백질-고분자 코어 쉘 구조 형성, 미세유체 제조기술을 이용한 단백질-고분자 나노구조체 형성, 초분자 조립 나노입자 형성의 분자 모델링 및 전산모사 연구, 바이러스 구조 단백질 재조합을 통한 바이러스 유사체 제작 및 백신효과 연구 등 선행 연구 수행하여 PNB 백신 기술개발의 가능성을 보였음

Abstract ▼

● The objective of this project is to develop size/function-controllable Protein NanoBall (PNB) technology for active responses against new strain virus. In addition, the size/function-controllable Protein NanoBall (PNB) can be produced with 10 days from the availability of genome information with 3

● The objective of this project is to develop size/function-controllable Protein NanoBall (PNB) technology for active responses against new strain virus. In addition, the size/function-controllable Protein NanoBall (PNB) can be produced with 10 days from the availability of genome information with 3 or more antigens on the surface with incorporation of adjuvant. Size of PNB should be uniform and within range of [50-300nm (± 5%)]
● Up to date, egg based influenza vaccines have limitations against to new strain virus, where the vaccines against the new strains or pandemic strains would not be satisfied with stability, high and flexible productivities, sizes, applications for rapid diagnosis, regulating number of antigens, density or ratio of antigens, orientations, supplements of immune-adjuvants, or inductions of B-cell or T-cell immunity. In the future, new technologies of next generation of vaccine should be developed to overcome the problems of existing vaccines. Thus, we proposed PNB technology as one of the potential solutions.
● The proposed PNB could make immunologically sufficient efficacy at low-dose with cost/time-saves in vaccine manufacturing. Moreover, multivalent hybrid vaccines could make the artificial antigens as virus mimicking high variable/pathogenic influenza. And PNB could be widely applied in diverse areas, such as drug delivery, imaging, sensing or bio-catalyst, due to its high expandability with materials and sizes. Particularly, the focused areas of artificial virus and diagnosis in this study could provide new application methods with realizations of collective properties of proteins. PNB based active responsive influenza vaccines could provide competitive advantages from the conventional vaccines, which may open avenues in export of bionanotechnology, and save medical and care expenses.
● Hence, the prior research planning of this projest was carries out in three major directions. The three major research directions are :
⊙ Designing of protein-polymer building blocks tailored for Protein NanoBall and developing of synthesis technology
◆ Design and synthesis of the protein-polymer hybrid assembly as a building block of artificial antigen PNB based on the technologies of protein-coding gene design/recombination/expression, precise synthesis of polymers and selective molecular recognition/coupling
◆ Research of manufacturing technology of a functional protein-polymer hybrid assembly by finding/designing/synthesizing optimal genes for function-determining proteins of PNB
◆ Creation of the most effective protein-polymer building block assembly for aiming applications and by introducing/synthesizing degradable polymers for effective encapsulations of active bio-materials and functions of PNB proteins
⊙ Molecular modeling of Protein NanoBall and in-situ assembly technique
◆ The correlations and significances between PNB assembly structure and protein-polymer hybrid assembly/supermolecules will be investigated through molecular modeling and computer simulations of the self-assembly
◆ The sizes/shapes of PNB from the microfluidic platforms will be performed after enabling self-assembly of PNB through inter-layer diffusion control, high accurate manufacturing processes, and evaluating fluidic properties.
⊙ High efficient Protein NanoBall with artificial antigens, vaccine assessment, and rapid diagnostic applications
◆ Fabricated PNB with binding polymer terminal groups and hemagglutinin (HA) and neuraminidase (NA) proteins from the annually predicted highly variable/pathogenic influenza.
◆ Design HA and NA on immune cells will be optimized to recognize the artificial antigens.
◆ The efficacy of the PNB will be assessed in cellular, mouse, and chicken models.
◆ The study of adsorption, distribution, metabolites, and excretion will be investigated.
◆ Point-of-care testing (POCT) system will be developed for rapidly evaluating the efficacy of PNB preventive vaccines.

목차 Contents

• 표지 ... 1
• 제 출 문 ... 2
• 보고서 요약서 ... 3
• 요 약 문 ... 4
• SUMMARY ... 9
• CONTENTS ... 11
• 목 차 ... 12
• 제 1 장 선행기획연구 개요 ... 13
• 1. 선행기획연구의 목적, 필요성 및 범위 ... 13
• 2. 대상 융합기술의 정의 및 개념 ... 20
• 제 2 장 기술개발 현황 및 조사ㆍ분석 ... 24
• 1. 국내ㆍ외 기술개발 현황 ... 24
• 2. 선행 연구 조사ㆍ분석 및 시사점 ... 34
• 제 3 장 기술개발 목표 및 내용 ... 59
• 1. 원천특허 포트폴리오 ... 59
• 2. 연구개발내용 및 범위 ... 74
• 3. 기존 기술과의 차별성 및 원천성 ... 88
• 4. 국가 R&D 전략과의 연계성 및 부합성 ... 92
• 5. 선행연구내용 및 결과 ... 96
• 제 4 장 선행기획연구 활동 추진내용 ... 106
• 1. 선행기획연구 추진 체계 ... 106
• 2. 선행기획연구 방법론 ... 108
• 3. 선행기획연구 활동 내용 ... 110
• 4. R&D 추진 전략 컨설팅 결과 반영 ... 117
• 제 5 장 기대성과 및 활용 계획 ... 126
• 1. 기대성과 ... 126
• 2. 상용화 예상 분야 ... 128
• 3. 경제성 분석 ... 129
• 제 6 장 참고문헌 ... 132
• 끝페이지 ... 134